The cellular uptake of J591-SPION-DTX by C4-2 (PSMA+) cells was remarkably high, suggesting the tumor specific targeting of this NDDP for targeted prostate cancer therapy [87]. This evidence concerns the gene FOLH1 and prostate cancer.